EMP-01
Social Anxiety Disorder
Phase 2Active
Key Facts
About atai Life Sciences
AtaiBeckley, formed from the strategic combination of atai Life Sciences and Beckley Psytech, is a global biotech leader focused on transforming mental healthcare through novel psychedelic-derived therapeutics. Its core strategy employs a decentralized platform to identify, incubate, and fund subsidiary programs, de-risking development across a diversified pipeline. Key near-term catalysts include Phase 2 readouts for its lead programs—BPL-003 and VLS-01 in treatment-resistant depression and EMP-01 in social anxiety disorder—positioning it at the forefront of a potentially paradigm-shifting treatment modality.
View full company profileTherapeutic Areas
Other Social Anxiety Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Fasedienol (PH94B) | Vistagen Therapeutics | Phase 3 |